ReviewCurrent neurology and neuroscience reports2016
Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm.
Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Differentiation-inducing triiodothyronine enhances chemotherapy and suppresses post-treatment tumor regrowth in medulloblastoma.Molecular therapy. Oncology · 2026Article
- Article
- Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtypes.Frontiers in immunology · 2026Review
- The Clinical Utility of Cell-Free DNA in Brain Tumor Management: A Comprehensive Review.Journal of molecular neuroscience : MN · 2025Review
- Genome-wide methylation and copy number variation analysis of medulloblastoma in a Saudi Arabian pediatric population.Annals of medicine and surgery (2012) · 2025Article
- Advances in CAR-T therapy for central nervous system tumors.Biomarker research · 2024Review
- Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals.Cellular and molecular neurobiology · 2022Review
- Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- Medulloblastoma: novel insights into emerging therapeutic targets.Expert opinion on therapeutic targets · 2021Article
- 3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome.The Journal of pathology · 2021Article
- Lipidome signatures of metastasis in a transgenic mouse model of sonic hedgehog medulloblastoma.Analytical and bioanalytical chemistry · 2020Article
- Erbb4 Is Required for Cerebellar Developmentand Malignant Phenotype of Medulloblastoma.Cancers · 2020Article
- Effective Inhibition ofCancer management and research · 2020Article
- Host Genome Variation is Associated with Neurocognitive Outcome in Survivors of Pediatric Medulloblastoma.Translational oncology · 2019Article
- Updates on Management of Adult Medulloblastoma.Current treatment options in oncology · 2019Review
- Transcriptional repressor REST drives lineage stage-specific chromatin compaction atScience signaling · 2019Article
- Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.Nature communications · 2019Article
- Medulloblastoma: optimizing care with a multidisciplinary approach.Journal of multidisciplinary healthcare · 2019Review
- Targeting mTOR as a Therapeutic Approach in Medulloblastoma.International journal of molecular sciences · 2018Review
- Functional expression of calcium-permeable canonical transient receptor potential 4-containing channels promotes migration of medulloblastoma cells.The Journal of physiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastoma is a malignant embryonic brain tumor arising in the posterior fossa and typically occurring in pediatric patients. Current multimodal treatment regimes have significantly improved the survival rates; however, a marked heterogeneity in therapy response is observed, and one third of all patients die within 5 years after diagnosis. Large-scale genetic and transcriptome analysis revealed four medulloblastoma subgroups (WNT, SHH, Group 3, and Group 4) associated with different demographic parameters, tumor manifestation, and clinical behavior. Future treatment protocols will integrate molecular classification schemes to evaluate subgroup-specific intensification or de-escalation of adjuvant therapies aimed to increase tumor control and reduce iatrogenic induced morbidity. Furthermore, the identification of genetic drivers allows assessing target therapies in order to increase the chemotherapeutic armamentarium. This review highlights the biology behind the current classification system and elucidates relevant aspects of the disease influencing forthcoming clinical trials.
Indexed as
Identifiers
27021772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.